GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT02244164

TerminatedPhase NA

Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

Lead sponsor

Erasme University Hospital

Assets

Exenatide / Liraglutide / Lixisenatide

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Type 2 diabetes

Key I/E criterion

•BMI 20-45

Primary endpoint

•Volumetric measurement of the pancreas

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02244164

Org study IDIncretine study

Timeline

Milestones

Study first posted2014-09-18estimated

Primary completion2023-02-13actual

Study completion2023-02-13actual

Last update posted2023-02-16actual

Study start2014-10 (month precision)

Assets

Investigational agents

Exenatide Liraglutide Lixisenatide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Type 2 diabetes inadequately controlled or intolerant to metformin

•Obtaining informed consent

•Aged between 18 and 70 years

•BMI between 20 and 45 kg / m²

Exclusion criteria

•Contraindication to nuclear magnetic resonance (NMR):

•Carrying a metallic foreign body (pacemaker, valve, intraocular equipment, clips)

•Allergy to Gadolinium / Secretin

•Pregnancy or breastfeeding

•Contraindication to treatment with incretinomimetic:

•Hypersensitivity to the active substance or to any of the excipients

•Severe Gastroparesis

•Severe renal impairment

•History of Surgery (gastroduodenal, pancreatic or ileocecal)

•Presence or history of pancreatic disease

•Active alcoholism

Endpoints (16)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)

Glycemic / diabetes

MASH / liver

Safety / tolerability / PK

Renal / kidney

Cardiometabolic biomarkers

Glycemic / diabetes

3 endpoints

Other/protocol endpoint

Fasting glycemia

Time frame:1 year

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Other/protocol endpoint

C-Peptide

Time frame:1 years

descriptive

Other/protocol endpoint

HbA1c

Time frame:1 year

HbA1c, change

change from baseline, improvement

LOINC 4548-4

MASH / liver

3 endpoints

Other/protocol endpoint

Gamma GT

Time frame:1 year

γ-GT, change

change from baseline, improvement

Other/protocol endpoint

Alanine aminotransferase

Time frame:1 year

ALT, change

change from baseline, improvement

LOINC 1742-6

Other/protocol endpoint

Asparate aminotransferase

Time frame:1 year

AST, change

change from baseline, improvement

LOINC 1920-8

Renal / kidney

1 endpoint

Other/protocol endpoint/low confidence

Creatininemia

Time frame:1 year

change from baseline, descriptive

Cardiometabolic biomarkers

1 endpoint

Other/protocol endpoint

Cholesterol

Time frame:1 year

Total cholesterol, change

change from baseline, improvement

LOINC 2093-3

Safety / tolerability / PK

2 endpoints

Other/protocol endpoint

Urea

Time frame:1 year

descriptive

Other/protocol endpoint

Bilirubinemia

Time frame:1 year

descriptive, event

Other (unclassified)

6 endpoints

Primary/protocol endpoint/low confidence

Volumetric measurement of the pancreas

Time frame:1 year

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Quantitative response to secretin

Time frame:1 year

descriptive

Other/protocol endpoint/low confidence

Calcium

Time frame:1 year

descriptive

Other/protocol endpoint/low confidence

Phosphorus

Time frame:1 year

descriptive

Other/protocol endpoint/low confidence

Alcaline phosphatase

Time frame:1 year

descriptive

Other/protocol endpoint/low confidence

Lipasemia

Time frame:1 year

descriptive

Publications (4)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?
Diabetes care2013 Jul (month)PMID23645885doi:10.2337/dc12-2713via CT.gov reference
Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.
Diabetes2013 Jul (month)PMID23524641doi:10.2337/db12-1686via CT.gov reference
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
JAMA2007 Jul 11PMID17622601doi:10.1001/jama.298.2.194via CT.gov reference
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Lancet (London, England)2006 Nov 11PMID17098089doi:10.1016/S0140-6736(06)69705-5via CT.gov reference

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.